General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Accord Healthcare Inc.
Indication:
For the treatment of adult patients with advanced prostate cancer
Last updated October 31, 2025
Status:
Concluded without agreement
Manufacturer:
Nordic Pharma
Indication:
Multiple Indications
Last updated October 30, 2025
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Multiple Indications
Last updated October 29, 2025
Abilify Asimtufii (aripiprazole)
Status:
Concluded with an LOI
Manufacturer:
Otsuka Canada Pharmaceutical Inc.
Indication:
Schizophrenia
Last updated October 24, 2025
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
For the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 [Combined Positive Score (CPS) ? 1], as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as monotherapy.
Last updated October 23, 2025
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
For the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT).
Last updated October 23, 2025
Ferinject (ferric carboxymaltose)
Status:
Concluded with an LOI
Manufacturer:
CSL Vifor
Indication:
Iron Deficiency Anemia
Last updated October 17, 2025
Ferinject (ferric carboxymaltose)
Status:
Concluded with an LOI
Manufacturer:
CSL Vifor
Indication:
Iron deficiency in adult patients with heart failure
Last updated October 17, 2025
Status:
Concluded with an LOI
Manufacturer:
Medison Pharma Canada Inc.
Indication:
Advanced Systemic Mastocytosis
Last updated October 17, 2025
Status:
Concluded with an LOI
Manufacturer:
Mantra Pharma
Indication:
Multiple Indications
Last updated October 14, 2025